OncoExTra®

The OncoExTra test helps physicians understand changes to a patient's genomic profile by providing a more complete molecular picture of advanced, metastatic, refractory, relapsed, or recurrent solid tumors. Knowing this information can help patients and physicians make informed choices when considering therapeutic treatment plans.
Lab equipment in Exact Sciences laboratory.

The full genomic story requires more than DNA alone

Ultra-comprehensive genomic profiling

Interrogating both DNA and RNA, the OncoExtra test provides ultra-comprehensive genomic profiling that thoroughly detects clinically actionable mutations and fusions.1 It delivers the all-encompassing genomic insights of whole-exome (DNA) and whole transcriptome (RNA) sequencing, highlighting key information that is critical to personalized cancer care.

Patient matched tumor-normal sequencing

The OncoExTra test utilizes patient-matched tumor-normal sequencing to further refine therapy selection. Patient-matched tumor-normal sequencing compares the sequence of genes in both somatic and germline DNA. This approach improves estimates of tumor mutational load and may better predict clinical benefit to immunotherapy with fewer false positives.2-4

Clinically actionable

In a clinical utilization study, 83.9% of OncoExTra test reports showed ≥1 clinically actionable variant.1*† The test's easy-to-interpret report highlights the most actionable insights for timely, shared decision-making:

  • Mutations and fusions associated with FDA-approved therapies
  • Immuno-oncology signatures (TMB/MSI) support personalized therapy selection
  • Clinical trial options to help inform next steps